Loading
Latest filing published 19 Nov 2025 for Protalix BioTherapeutics, Inc., €271.
No signal scores available.
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by Amos Bar-Shalev on record concern Protalix BioTherapeutics, Inc. Between 31 December 2006 and 18 November 2025, the trades on record add up to 5 filings.
On the open market, the record shows 2 purchases worth €9,460 and 1 sale worth €271. Purchases outweigh sales by €9,189. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 2 share grants. Since January 2025: no purchases and 1 sale on the market.
Most recently, on 19 November 2025, the filings show an open-market sale worth €271 in Protalix BioTherapeutics, Inc. The most recent open-market purchase was published on 9 December 2009, 6,162 days ago. Filings reach the SEC (Form 4) feed a median of 5 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations